Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Exosome complex Stories

2013-10-15 08:31:57

SAN DIEGO, Oct. 15, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Logo: http://photos.prnewswire.com/prnh/20130912/LA78266LOGO) (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) In recent months, we launched and staffed a diagnostic subsidiary, expanded our intellectual property portfolio, and continued to generate revenues from established and newly awarded government...

2012-08-20 16:30:14

Scientists have cracked a molecular code that may open the way to destroying or correcting defective gene products, such as those that cause genetic disorders in humans. The code determines the recognition of RNA molecules by a superfamily of RNA-binding proteins called pentatricopeptide repeat (PPR) proteins. When a gene is switched on, it is copied into RNA.  This RNA is then used to make proteins that are required by the organism for all of its vital functions.  If a gene...

The Key To Self-renewing Skin
2012-07-05 13:45:19

In the July 6 issue of Cell Stem Cell, researchers at the University of California, San Diego School of Medicine describe how human epidermal progenitor cells and stem cells control transcription factors to avoid premature differentiation, preserving their ability to produce new skin cells throughout life. The findings provide new insights into the role and importance of exosomes and their targeted gene transcripts, and may help point the way to new drugs or therapies for not just skin...

2012-06-12 06:25:39

SAN DIEGO, June 12, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) Last week, Medical News Today reported on a cancer research discovery that reinforces the potential importance of our therapeutic endeavors. For more than a century, cancer researchers have understood that certain forms of cancer only spread to specific, preferred...

2012-06-04 02:26:09

NEW YORK, June 4, 2012 /PRNewswire/ -- Exosome Diagnostics today announced it has reached agreement with Life Technologies to use the Applied Biosystems® (ABI) 7500 Fast Dx Real-Time PCR Instrument for the Company's exosome biofluid in-vitro diagnostics oncology program. Exosome Diagnostics plans to validate the ABI instrument platform with exosome biofluid RNA isolation technology kits in upcoming multi-center clinical trials in brain cancer and prostate cancer beginning in...

2012-05-23 06:25:52

NEW YORK, May 23, 2012 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic tests for use in personalized and non-invasive cancer diagnostics, today presented two clinical studies demonstrating the potential utility of non-invasive sampling of patients' urine to detect and manage prostate cancer. In the first study, the presence of a prostate cancer-specific biomarker in exosomes collected from random patients' urine samples demonstrated a strong...

2012-03-28 02:24:16

NEW YORK, March 28, 2011 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic tests for use in personalized and non-invasive cancer diagnostics, today announced that Kapil Dhingra, M.B, B.S., has joined the Exosome Diagnostics Board of Directors. "I am delighted to join the Board of Exosome Diagnostics at this critical stage in the evolution of the company. Cancer treatment is becoming increasingly personalized. The ability to perform repeated,...

2012-02-06 07:00:00

WASHINGTON and NEW YORK, Feb. 6, 2012 /PRNewswire/ -- Accelerate Brain Cancer Cure (ABC2) and Exosome Diagnostics are collaborating with leading academic medical centers to accelerate clinical validation of Exosome's blood and cerebrospinal fluid-based molecular diagnostics technology in brain cancer. The collaboration will explore the capabilities of Exosome RNA biofluid-based diagnostic technology for early identification, progression monitoring and disease risk stratification...

2012-02-01 07:00:00

MUNICH, Feb. 1, 2012 /PRNewswire/ -- Exosome Diagnostics GmbH, a subsidiary of Exosome Diagnostics, Inc., and the Department of Dermatology at the Ludwig Maximilian University (LMU) announces the awarding of a EUR one million grant from the German Federal Ministry for Education and Research (BMBF) to develop blood-based diagnostic tests from the stable RNA content accessible in plasma-derived exosomes. The grant will help fund development of exosome-based diagnostics technology to...

2011-10-18 08:15:00

SAN DIEGO, Oct. 18, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it will begin accepting orders for its Enzyme Linked Lectin Specific Assay (ELLSA(TM)) from researchers that require a highly sensitive diagnostic tool to detect the presence of exosomes in cell culture, ascites, and other biological fluids, including blood. (Photo:...